These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24884602)

  • 41. Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials.
    Farnier M; Marcereuil D; De Niet S; Ducobu J; Steinmetz A; Retterstøl K; Bryniarski L; Császár A; Vanderbist F
    Clin Drug Investig; 2012 Apr; 32(4):281-91. PubMed ID: 22350498
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine.
    Camporeale A; Kudrow D; Sides R; Wang S; Van Dycke A; Selzler KJ; Stauffer VL
    BMC Neurol; 2018 Nov; 18(1):188. PubMed ID: 30413151
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease.
    Sibley CH; Chioato A; Felix S; Colin L; Chakraborty A; Plass N; Rodriguez-Smith J; Brewer C; King K; Zalewski C; Kim HJ; Bishop R; Abrams K; Stone D; Chapelle D; Kost B; Snyder C; Butman JA; Wesley R; Goldbach-Mansky R
    Ann Rheum Dis; 2015 Sep; 74(9):1714-9. PubMed ID: 24906637
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study.
    Chioato A; Noseda E; Felix SD; Stevens M; Del Giudice G; Fitoussi S; Kleinschmidt A
    Clin Vaccine Immunol; 2010 Dec; 17(12):1952-7. PubMed ID: 20962212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.
    Feist E; Quartier P; Fautrel B; Schneider R; Sfriso P; Efthimiou P; Cantarini L; Lheritier K; Leon K; Karyekar CS; Speziale A
    Clin Exp Rheumatol; 2018; 36(4):668-675. PubMed ID: 29533755
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.
    So A; De Meulemeester M; Pikhlak A; Yücel AE; Richard D; Murphy V; Arulmani U; Sallstig P; Schlesinger N
    Arthritis Rheum; 2010 Oct; 62(10):3064-76. PubMed ID: 20533546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
    De Benedetti F; Gattorno M; Anton J; Ben-Chetrit E; Frenkel J; Hoffman HM; Koné-Paut I; Lachmann HJ; Ozen S; Simon A; Zeft A; Calvo Penades I; Moutschen M; Quartier P; Kasapcopur O; Shcherbina A; Hofer M; Hashkes PJ; Van der Hilst J; Hara R; Bujan-Rivas S; Constantin T; Gul A; Livneh A; Brogan P; Cattalini M; Obici L; Lheritier K; Speziale A; Junge G
    N Engl J Med; 2018 May; 378(20):1908-1919. PubMed ID: 29768139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interleukin-1 inhibitors for acute gout.
    Sivera F; Wechalekar MD; Andrés M; Buchbinder R; Carmona L
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD009993. PubMed ID: 25177840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
    Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
    Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients.
    Atula S; Powles T; Paterson A; McCloskey E; Nevalainen J; Kanis J
    Drug Saf; 2003; 26(9):661-71. PubMed ID: 12814333
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Stenlöf K; Cefalu WT; Kim KA; Alba M; Usiskin K; Tong C; Canovatchel W; Meininger G
    Diabetes Obes Metab; 2013 Apr; 15(4):372-82. PubMed ID: 23279307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies.
    Toth PP; Descamps O; Genest J; Sattar N; Preiss D; Dent R; Djedjos C; Wu Y; Geller M; Uhart M; Somaratne R; Wasserman SM;
    Circulation; 2017 May; 135(19):1819-1831. PubMed ID: 28249876
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
    Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y
    Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.
    Everett BM; Cornel JH; Lainscak M; Anker SD; Abbate A; Thuren T; Libby P; Glynn RJ; Ridker PM
    Circulation; 2019 Mar; 139(10):1289-1299. PubMed ID: 30586730
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study.
    Donohue JF; Niewoehner D; Brooks J; O'Dell D; Church A
    Respir Res; 2014 Jul; 15(1):78. PubMed ID: 25015176
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-Blind Placebo-Controlled Single-Center Study.
    Maul JT; Distler M; Kolios A; Maul LV; Guillet C; Graf N; Imhof L; Lang C; Navarini AA; Schmid-Grendelmeier P
    J Allergy Clin Immunol Pract; 2021 Jan; 9(1):463-468.e3. PubMed ID: 32827729
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942.
    Burgess G; Boyce M; Jones M; Larsson L; Main MJ; Morgan F; Phillips P; Scrimgeour A; Strimenopoulou F; Vajjah P; Zamacona M; Palframan R
    EBioMedicine; 2018 Sep; 35():67-75. PubMed ID: 30146344
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry.
    Walker UA; Tilson HH; Hawkins PN; Poll TV; Noviello S; Levy J; Vritzali E; Hoffman HM; Kuemmerle-Deschner JB;
    RMD Open; 2021 May; 7(2):. PubMed ID: 34001647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.